---
title: "WuXi XDC Dispatches Offer Document for Cash Takeover of TOT BIOPHARM"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275675866.md"
description: "WuXi XDC Cayman Inc. has sent out an offer document for a voluntary cash takeover of TOT BIOPHARM International Co. Ltd. (HK:1875), excluding shares already held by the offeror. The offer starts on 12 February 2026, with key deadlines extending to mid-March. The latest analyst rating for TOT BIOPHARM is a Hold, with a price target of HK$4.50. TOT BIOPHARM focuses on developing oncology and biologic therapies and is listed on the Hong Kong Stock Exchange, with a market cap of HK$3.25B."
datetime: "2026-02-11T22:37:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275675866.md)
  - [en](https://longbridge.com/en/news/275675866.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275675866.md)
---

# WuXi XDC Dispatches Offer Document for Cash Takeover of TOT BIOPHARM

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has provided an announcement.

WuXi XDC Cayman Inc. has formally dispatched the composite offer and response document for its voluntary conditional cash offers to acquire all issued shares of TOT BIOPHARM International Co. Ltd., excluding those already held or agreed to be acquired by the offeror and its concert parties, and to cancel all outstanding share options. The despatch, which includes the offer terms, timetable and independent advice to shareholders and option holders, sets 12 February 2026 as the commencement date of the offers and outlines key deadlines through mid‑March, marking a key step in the proposed takeover process and giving investors a defined window to consider and respond to the bid.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

**More about TOT BIOPHARM International Co. Ltd.**

TOT BIOPHARM International Co. Ltd. operates in the biopharmaceutical sector, focusing on the development and commercialization of oncology and other biologic therapies, and is listed on the Hong Kong Stock Exchange. The company targets both domestic and international markets with a portfolio of innovative drugs and related services aimed at addressing unmet medical needs.

**Average Trading Volume:** 2,932,065

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$3.25B

### Related Stocks

- [02268.HK](https://longbridge.com/en/quote/02268.HK.md)
- [01875.HK](https://longbridge.com/en/quote/01875.HK.md)

## Related News & Research

- [BioDlink Appoints Independent Adviser for WuXi XDC’s Conditional Takeover Offer](https://longbridge.com/en/news/272976665.md)
- [Artivion Completes Acquisition of Endospan Ltd. | AORT Stock News](https://longbridge.com/en/news/286758893.md)
- [Micware Co., Ltd. Announces Closing of Upsized Initial Public Offering | MWC Stock News](https://longbridge.com/en/news/286607672.md)
- [Island Pharmaceuticals Strengthens Biodefence Engagement for Galidesivir Advancement](https://longbridge.com/en/news/286834766.md)
- [Nanjing Leads Biolabs Wins Phase III Green Light for Key Cancer Drug Opamtistomig](https://longbridge.com/en/news/286828874.md)